Original title: Tencent invested in circular RNA vaccine developer Yuanyin Biology The Wei Wensheng team at Peking University is developing a new crown vaccine
IT home May 11 news, information shows that recently, Yuanyin (Beijing) Biotechnology Co., Ltd. underwent industrial and commercial changes, shareholders added Guangxi Tencent Venture Capital Co., Ltd., at the same time, the company's registered capital increased from about 1.5589 million yuan to about 2.1564 million yuan.
According to reports, Yuanyin (Beijing) Biotechnology Co., Ltd. was founded by Professor Wei Wensheng of Peking University in April 2021 to study the research and application of cyclic RNA technology in the field of innovative drugs and innovative therapies.
Not long ago, Wei Wensheng's research group published a research paper showing that the circular RNA vaccine prepared by the team against the Delta strain of the new coronavirus has broad-spectrum protection against a variety of new coronavirus variants.
User comments